JSS.F Sosei Group Corporation

Healthcare Biotechnology Frankfurt Exchange
10.10 EUR
Close of Nov 13, 2026
4.04 10.10
Market cap
EUR 926M
P/E
-
P/B
2.55x
ROE
4.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is JSS.F undervalued?

Graham number

The Graham number of Sosei Group Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sosei Group Corporation fundamental analysis

No fundamental analysis for Sosei Group Corporation yet.

Sosei Group Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sosei Group Corporation

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 ago…

Full company profile